Senya Therapeutics is developing proprietary biologics targeting LRG1. The lead compound is STX-001 (Magacizumab) which is being developed to treat chronic kidney disease and an undisclosed fibrotic disease. STX-001 has shown good efficacy and safety in several preclinical models.
Senya Is Developing An Extensive Portfolio Of Anti-LRG1 Therapeutics
STX-001 (magacizumab)
A fully humanised function-blocking antibody against LRG1, isolated and developed from an original panel of more than 100 mouse monoclonals. With high affinity and specificity, and with manufacturing protocols already in place, Magacizumab is ready for delivery to patients with a variety of clinical indications. Despite its overall excellent therapeutic profile, Senya are currently working on potential enhancements.
STX-002
Currently in development, a bi-specific antibody targeting both LRG1 and immune checkpoints with a focus on treating cancer. Based on our published findings that simultaneous checkpoint and LRG1 inhibition substantially improved therapeutic efficacy, we see a compelling rationale for blocking these distinct tumour promoting pathways via a single novel therapeutic.
